- Home
- FOLD vs PRGS Comparison
FOLD vs PRGS Comparison
Compare FOLD & PRGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOLD
- PRGS
- Stock Information
- Founded
- FOLD 2002
- PRGS 1981
- Country
- FOLD United States
- PRGS United States
- Employees
- FOLD N/A
- PRGS N/A
- Industry
- FOLD Biotechnology: Pharmaceutical Preparations
- PRGS Computer Software: Prepackaged Software
- Sector
- FOLD Health Care
- PRGS Technology
- Exchange
- FOLD Nasdaq
- PRGS Nasdaq
- Market Cap
- FOLD 2.9B
- PRGS 2.4B
- IPO Year
- FOLD 2007
- PRGS 1991
- Fundamental
- Price
- FOLD $6.16
- PRGS $61.81
- Analyst Decision
- FOLD Buy
- PRGS Buy
- Analyst Count
- FOLD 10
- PRGS 7
- Target Price
- FOLD $16.22
- PRGS $73.71
- AVG Volume (30 Days)
- FOLD 5.0M
- PRGS 411.4K
- Earning Date
- FOLD 05-01-2025
- PRGS 06-24-2025
- Dividend Yield
- FOLD N/A
- PRGS 0.28%
- EPS Growth
- FOLD N/A
- PRGS N/A
- EPS
- FOLD N/A
- PRGS 1.27
- Revenue
- FOLD $543,141,000.00
- PRGS $806,739,000.00
- Revenue This Year
- FOLD $19.85
- PRGS $30.62
- Revenue Next Year
- FOLD $23.50
- PRGS $2.43
- P/E Ratio
- FOLD N/A
- PRGS $48.75
- Revenue Growth
- FOLD 28.25
- PRGS 12.85
- 52 Week Low
- FOLD $5.81
- PRGS $48.00
- 52 Week High
- FOLD $12.65
- PRGS $70.56
- Technical
- Relative Strength Index (RSI)
- FOLD 41.91
- PRGS 56.28
- Support Level
- FOLD $6.03
- PRGS $60.44
- Resistance Level
- FOLD $6.37
- PRGS $62.37
- Average True Range (ATR)
- FOLD 0.24
- PRGS 1.00
- MACD
- FOLD 0.04
- PRGS -0.27
- Stochastic Oscillator
- FOLD 41.67
- PRGS 62.66
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
About PRGS Progress Software Corporation (DE)
Progress Software Corporation provides software operate in one operating segment: software products for the development, deployment, and management of responsible, AI-powered applications and digital experiences. Following are products: Chef, Corticon, Data Direct, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, WhatsUp Gold. Geographical regions include United States, Canada, EMEA, Latin America, and Asia Pacific.